Psilocybin and Alzheimer's: What One Case Report Really Tells Us
For families living through Alzheimer's, the cruelty isn't only the memory loss. It's watching the person recede, piece by piece. The voice, the humor, the presence, the recognition all start to thin out, until what's in the room with you feels like less and less of who they were.
So a new case report got my attention. An octogenarian woman with advanced Alzheimer's, roughly ten years into the disease, appeared to show striking but temporary improvements after taking psilocybin-containing mushrooms in a supervised setting. It's one of the first times psilocybin and Alzheimer's have been documented together in a clinical write-up like this.
It's not a cure story. It may be a clue. And when you've watched dementia take someone you love, a clue is not nothing.
Why this hit me
My grandmother had dementia, and watching it was devastating. She stopped remembering my name. She'd lose track of what day / year it was, or what was happening around her. There were stretches where she regressed into something almost infant-like: frightened, crying, helpless, unable to make sense of why she felt so lost.
There's no clean way to describe what that does to a family. You're grieving someone who is still in the room.
So I don't read a case report like this clinically. The question it raises is the one that's hard to put down: what if some of what we thought be going gone forever is actually still in there, buried and blocked and unreachable by ordinary means, rather than erased?
That's not a claim. It's a question. But for anyone living in the grief of "everything's gone…or soon to be," it's a question worth sitting with.
What the case report actually describes
Before the intervention, the woman had been in steep decline for years. The authors describe predominantly monosyllabic speech for about five years, along with chronic urinary incontinence, difficulty walking and swallowing, flat affect, and near-total dependence on caregivers.
She took a single 5-gram oral dose of psilocybin-containing mushrooms (the "Enigma" strain), supervised, with family present.
Roughly 19 hours later, she emerged from a long, deep, sleep-like state and began speaking spontaneously about her own life. Several hours of autobiographical conversation, after years of saying almost nothing.
In the days and weeks after, the reported changes went past speech: steadier walking, dressing herself, restored bladder control, more eye contact, reciprocal smiling, recognizing family, more social engagement. At one month she was still functioning above her baseline. A second supervised session was associated with more verbal expression, humor, emotional responsiveness, and better mobility.
Not just words. Her words. Her memories. Her life, at least for a while.
Hold this loosely: the limits of one case
Here's the part the hype machine will skip, and the part that actually matters.
This is a single case report, the weakest tier of medical evidence there is. One patient. No control group. No standardized cognitive testing before and after. No brain imaging. The Alzheimer's diagnosis was clinical, not confirmed with modern biomarkers. The improvements were temporary. And the report comes out of a small private clinic in Brazil, not a research hospital running a controlled trial.
So we cannot say psilocybin caused the improvements. We cannot say it "works" for Alzheimer's. We cannot say it's safe for people with dementia.
What we can say is narrower and still interesting: in this one person, abilities everyone assumed were permanently lost turned out to be temporarily accessible under the right conditions. The authors frame it as residual capacity that may persist in late-stage neurodegeneration and become briefly reachable: dormant, not dead. That's a hypothesis worth testing. It is not a result.
Psychedelic Integration in NYC
As interest in psychedelic healing grows, New York City has become home to a diverse and expanding psychedelic community.
Today, New Yorkers have access to:
Integration coaches
Mental health professionals familiar with psychedelics
Peer support groups
Community integration circles
Educational workshops
Harm reduction resources
Finding the right support depends on your needs, goals, and preferences.
Some people benefit from one-on-one integration support, while others find value in group settings where they can connect with others who have had similar experiences.
How to Find the Right Psychedelic Integration Support
If you're looking for psychedelic integration support in NYC, consider asking:
Is the approach grounded and non-judgmental?
You should feel safe discussing your experience openly without pressure, dogma, or predetermined interpretations.
Does the provider understand consent and boundaries?
Healthy psychedelic support respects personal agency and recognizes that each individual's experience is unique.
Is the provider trauma-informed?
Psychedelic experiences can surface vulnerable emotional material. Trauma-informed support helps ensure these experiences are approached thoughtfully and responsibly.
Does the support focus on real-life integration?
The goal of integration is not simply talking about psychedelic experiences. It's helping people create meaningful change in their everyday lives.
Healing Happens Beyond the Experience
One of the most important lessons many people learn is that psychedelic healing does not happen in isolation.
While psychedelic experiences can open doors, meaningful transformation often occurs through reflection, community, relationships, and consistent integration work afterward.
In many ways, psychedelic integration is where the deeper work begins.
The experience may last a few hours.
Integration can last a lifetime.
Why researchers are studying psilocybin and the aging brain
Psilocybin is the psychedelic compound in certain mushrooms. Most of the modern research has looked at depression, anxiety, addiction, and end-of-life distress. The interest in aging is newer, and it largely comes down to one word: neuroplasticity, the brain's capacity to adapt and form new connections.
In animal models, psilocybin appears to increase synaptic connections in regions tied to memory, including the hippocampus and prefrontal cortex. Whether that translates to anything meaningful in older humans, let alone people with Alzheimer's, is genuinely unknown.
UC Berkeley's Center for the Science of Psychedelics recently launched PLASTICITY, billed as the first psychedelic neuroimaging study focused on older adults. It's worth being precise about what it is and isn't: it enrolls cognitively healthy adults aged 60 to 85 and uses MRI to track how a single dose of psilocybin affects memory, perception, emotion, and brain structure. It is not a dementia treatment study. Notably, older adults have been almost entirely excluded from modern psychedelic research. One 2024 review put them at about 1.4% of all participants, so even basic safety and dose-response data in this group is thin.
Why caution matters, especially for older adults
I do integration and harm-reduction work, so I'm not going to write a hopeful post about mushrooms and dementia without saying this plainly: this is not something to try at home, and a case report is not permission.
Psilocybin is not gentle on every body. For older adults specifically, the risks are real: falls, cardiovascular strain, interactions with medications, and the simple fact that a psychedelic experience can be frightening and disorienting, especially for someone who can't fully understand what's happening to them. Several of these cautions are laid out well in a careful explainer in The Conversation. A supervised clinical setting did the heavy lifting in this case. Recreating that informally, with a vulnerable elder, is a different and far riskier thing.
If this research goes anywhere, it'll be because careful people studied it carefully. The honest move for the rest of us is to stay curious and stay patient.
A bigger question than the molecule
Set the mushrooms aside for a second, because the deeper question outlasts any single compound: what if part of what we read as "gone" in advanced dementia is presence we've stopped knowing how to reach?
As more families face this in the coming years, I'd want our idea of good care to hold two things at once. Better treatments, yes, but also better systems around the person: caregivers who are supported instead of crushed, communities that don't quietly disappear the elderly, models of care that protect dignity rather than just managing decline.
Whether psilocybin ends up being part of that picture, nobody knows yet. But the question this case points at is worth keeping.
What if Alzheimer's care could mean more than slowing the loss? What if, sometimes, it could mean restoring a moment of presence: one more real conversation, one more laugh, one more look of recognition?
That's not certainty. It's a reason to keep asking better questions.
This post is educational and reflects emerging, very preliminary research. It is not medical advice and not a treatment recommendation. Psilocybin is not an approved treatment for Alzheimer's disease, and the case discussed here was conducted under clinical supervision.
Josh Jupiter is a psychedelic integration coach and founder of Brooklyn Balance, a wellness practice in Brooklyn, New York. This article is for educational and informational purposes only and does not constitute medical or legal advice. For guidance on any of the therapeutic options discussed, please consult a qualified healthcare provider. For information on clinical trials, visit ClinicalTrials.gov.
Ready to go deeper? Reach out to Josh to learn about one-on-one integration coaching, group programs, and upcoming workshops at Brooklyn Balance.